DP方案联合参芪扶正注射液治疗晚期非小细胞肺癌40例疗效评价

摘要

目的：评价DP胡里奥方案联合参芪扶正注射液治疗Ⅲb~Ⅳ期非小细胞肺癌的临床疗效。方法将80例Ⅲb~Ⅳ期非小细胞肺癌患者随机均分为两组，各40例。治疗组予DP化学治疗(简称化疗)方案（多西他赛75 mg/m2、第1天给药，顺铂25 mg/m2静脉滴注、第1~3天给药，均静脉滴注）联合参芪扶正注射液（初始化疗第1天开始连续静脉滴注250 mL，滴注14 d后，间歇7 d，每21 d为1个周期）治疗，对照组单用 DP化疗方案。至少2个周期后评价疗效、卡氏生活质量（KPS）评分改善情况及T淋巴细胞亚群（CD3+，CD4+， CD8+，CD4+/CD8+）和NK细胞比例。结果治疗组有效率（32.50%）较对照组（25.00%）高，但差异无统计学意义（ P﹥0.05）；治疗组KPS评分改善情况优于对照组（ P﹤0.05）；治疗组CD3+，CD4+，CD8+，CD4+/CD8+，NK细胞治疗前后比较差异无统计学意义，对照组除CD8+外均较治疗前下降，且治疗组治疗后各指标水平均显著高于对照组治疗后（ P﹤0.05）。结论 DP化疗方案联合参芪扶正注射液治疗Ⅲb~Ⅳ期非小细胞肺癌疗效较好，可使KPS评分得到改善并提高患者的免疫功能。%Objective To evaluate the clinical therapeutic effect of DP regimen combined with Shenqifuzheng Injection on Ⅲb-Ⅳ stage of non-small cell lung cancer(NSCLC). Methods 80 patients with Ⅲb-Ⅳ stage of NSCLC were randomly divided into two groups, 40 cases in each group. The treatment group was treated by the DP regimen,docetaxel 75 mg/m2 by intravenous drip on 1 d and cis-platin 25 mg/m2 by intravenous drip on 1-3 d,which combined with Shenqifuzheng Injecfion 250 mL by intravenous drip for succes-sive 14 d,then intermittent 7 d,with 21 d as a treatment cycle. The control group only received the DP regimen. After at least 2 cy-cles of treatment,the curative efficacy,improvement of the Karnofsky Performance Scale(KPS)scores,T lymphocyte subsets(CD3+,CD4 +, CD8 +,CD4+ /CD8+) and NK cells proportion were evaluated in the two groups. Results The total effective rate after 2 cycles of treatment in the treatment group was 32. 50%,which was higher than 25. 00% in the control group,but the difference between the two groups had no statistical significance( P ﹥ 0. 05);the improvement situation of KPS scores in the treatment group was significantly bet-ter than that in the control group( P ﹤ 0. 05);CD3+,CD4 +,CD8 +,CD4 + /CD8+ and NK cells in the treatment group had no statistical differences between before and after treatment( P ﹥ 0. 05),which except CD8+ in the control group were decreased compared with be-fore treatment,moreover the levels of various indexes after treatment in the treatment group were significantly higher than those in the control( P ﹤ 0. 05). Conclusion The DP chemotherapy regimen combined with Shenqifuzheng Injection can achieve better efficacy for treating Ⅲb-Ⅳ stage of NSCLC,can improve the KPS scores and increase the immune function of patients.